Persantine and aspirin in coronary heart disease. The Persantine-Aspirin Reinfarction Study Research Group.
Persantine and aspirin in coronary heart disease. The Persantine-Aspirin Reinfarction Study Research Group.
复制标题
佩生汀和阿司匹林治疗冠心病。
DOI：
10.1161/01.cir.62.3.449
复制
发表时间：
1980
期刊：
影响因子：
37.8
通讯作者：
L. Wilkins
中科院分区：
文献类型：
--
作者：
L. Wilkins
在潘生丁-阿司匹林再梗死研究（巴黎）试验中，2026名心肌梗死（MI）康复者被随机分为三组：潘生丁+阿司匹林（PR/A）（n = 810）;阿司匹林单药（阿萨）（n = 810）;安慰剂（PLBO）（n = 406）。平均随访时间为41个月。三个指定的主要终点的结果是：与PLBO相比，PR/A组总死亡率降低16%，阿萨组降低18%;冠状动脉死亡率降低24%和21%;非致命性MI加致命性冠状动脉疾病的发生率降低25%和24%。根据研究标准（Z大于或等于2.6），这些差异不具有统计学显著性。通过生命表分析，PR/A组的冠状动脉死亡率和冠状动脉发病率在8-24个月内比PLBO组低约50%，并且对于冠状动脉发病率，所有Z值均大于或等于2.6;阿萨率比PLBO率低约30%，并且对于冠状动脉发病率，Z值在两个点大于或等于2.6。对于这些终点，从8-20个月，PR/A率比阿萨率低约30%，但所有Z值均小于2.0 PR/A，并且在末次MI后6个月内入组的阿萨患者显示死亡率降低的百分比最大;只有PR/A组和PLBO组之间3年冠状动脉死亡率的差异产生Z值2.6。
In the Persantine-Aspirin Reinfarction Study (PARIS) trial, 2026 persons who had recovered from myocardial infarction (MI) were randomized into three groups: Persantine plus aspirin (PR/A) (n = 810); aspirin alone (ASA) (n = 810); placebo (PLBO) (n = 406). The average length of follow-up study was 41 months. Results for the three specified primary end points were: total mortality 16% lower in PR/A and 18% lower in ASA compared with PLBO; coronary mortality 24% and 21% lower; incidence of nonfatal MI plus fatal coronary disease 25% and 24% lower. These differences were not satistically significant by the study criterion (Z greater than or equal to 2.6). By life-table analysis, the rates of coronary mortality and coronary incidence were about 50% lower in the PR/A group than in the PLBO group from 8-24 months, and for coronary incidence all Z values were greater than or equal to 2.6; ASA rates were about 30% lower than PLBO rates, and for coronary incidence, Z values were greater than or equal to 2.6 at two points. For these end points, from 8-20 months, PR/A rates were about 30% lower than ASA rates, but all Z values were less than 2.0 PR/A and ASA patients entering within 6 months of last MI showed the largest percentage reductions in mortality; only the difference between PR/A and PLBO groups for 3-year coronary mortality yielded a Z value of 2.6.